Johnson & Johnson Raises Full-Year Sales Outlook Amid Strong Pharmaceutical Growth
On its third-quarter earnings call on October 13, 2026, Johnson & Johnson reported strong performance driven by robust pharmaceutical demand and raised its full-year sales outlook. The company is projected to cross $100 billion in annual revenue for the first time in its history due largely to growth from its Innovative Medicine division, particularly in cancer treatments and products like Tremfya. The medical device segment faced headwinds globally but management expressed confidence in restoring double-digit growth through new product launches such as OTTAVA. Additionally, Johnson & Johnson is considering a tax-free spinoff of DePuy Synthes by mid-2027 to streamline operations and focus on internal investments rather than major acquisitions. Looking ahead, the company anticipates continued momentum into 2027 with high-margin oncology treatments and new surgical device rollouts. Leadership remains optimistic about achieving double-digit growth over the next decade.
Tickers: $JNJ
Topics: divestitures medical devices pharmaceuticals sales growth
Read the full article at Motley Fool
Part of the story Sigma Foods Reports Record 3Q26 EBITDA and Raises Full-Year Guidance (21 articles)